Navigation Links
BELLUS Health announces formal notice to voluntarily delist from NASDAQ
Date:12/17/2008

BELLUS Health Successfully Completed and Closed the Amendment of the

--------------------------------------------------------------------

Trust Indenture Governing the November 2006 Notes

-------------------------------------------------

LAVAL, QC, Dec. 17 /PRNewswire-FirstCall/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU) announces that it has provided formal notice to the NASDAQ Stock Market of its intention to voluntarily delist its common stock from the NASDAQ Capital Market. The decision was taken in light of the continuing, extreme short-term volatility in current conditions in the financial markets and, accordingly, in the Company's market value. The Company expects that it will file a Form 25 with the Securities and Exchange Commission and NASDAQ on or about December 29, 2008, with delisting of its common stock to take effect ten days thereafter. The Company's listing on the Toronto Stock Exchange (TSX: BLU) will not be affected by this action. The Company will continue to be subject to the filing and other obligations of the U.S. securities laws applicable to non-U.S. reporting companies during 2009.

Having received the consent of the holders of over a majority in value of the Company's $42,085,000 aggregate principal amount of 6% convertible senior notes issued in November 2006 (the Notes), the Company amended the trust indenture governing the Notes, so as to permit delisting from NASDAQ.

As previously announced, the Company received a Deficiency Letter dated December 1, 2008, from the NASDAQ Staff stating that, for 10 consecutive trading days, the market value of the Company's listed securities had been below the minimum $35,000,000 requirement for continued inclusion on the NASDAQ Capital Market under Marketplace Rule 4310(c)(3)(B).

About BELLUS Health

BELLUS Health is a global health company focused on the development and commercialization of products to provide innovative health solutions to address critical unmet needs.

To Contact BELLUS Health

For additional information on BELLUS Health and its drug development programs, please call the Canada and United States toll-free number 1-877-680-4500 or visit the Web Site at www.bellushealth.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the BELLUS Health Group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of BELLUS Health Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and BELLUS Health Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see the Annual Information Form of BELLUS Health Inc. for further risk factors that might affect the BELLUS Health Group and its business.

CONTACT: Lise Hebert, Ph.D., Vice President, Corporate Communications, (450) 680-4572, lhebert@bellushealth.com


'/>"/>
SOURCE BELLUS HEALTH INC.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
2. BELLUS HEALTH reports results for first quarter of fiscal 2008
3. BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
4. BELLUS Health announces closing of Innodia acquisition
5. BELLUS Health provides update on activities
6. BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference
7. BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update
8. BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
9. BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market
10. Penn study finds pro-death proteins required to regulate healthy immune function
11. UCLA researchers identify markers that may predict diabetes in still-healthy people
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... ... (KOHP), a $500,000 two-year pilot initiative to improve oral health-related awareness, education, prevention ... development for health care providers and promote best practices in 10 New Jersey ...
(Date:5/25/2016)... ... ... The Bank of America Charitable Foundation has awarded a grant to the General ... employment and successful careers in healthcare. On Wednesday, May 4th, Rick Bridwell, Bank of ... Medisend, parent organization and home of the General Myers Veterans Program. , “The ...
(Date:5/25/2016)... ... May 25, 2016 , ... Today ... Herbert Wertheim College of Medicine announced the AUA-FIU Global MD Program. Students ... Health Certificate from AUA and a Certificate of Completion from the FIU Herbert ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... Dr. Travis ... Woodlawn Plaza at 8618 Mexico Road, O’Fallon, MO 63366. He serves patients of all ... cosmetic treatments . Dr. Schwarz’s success is reflected in the superior patient reviews ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... Today Omega ... launch of 11 innovative workshops and training opportunities in the growing field ... unique needs of individuals who are dealing with specific health issues—including injuries, illnesses, and ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, 2016 ... ; Frankfurt Prime Standard: QIA) today announced that the company ... Diagnostics GmbH to develop and commercialize predictive assays in oncology. ... as a marker to predict effectiveness of anthracycline treatment in ... "We are pleased to partner with Therawis, which developed the ...
(Date:5/25/2016)... May 25, 2016  According to Kalorama Information, the ... in 2015.  Though these are challenging times in ... for success for companies that remain optimistic and ... new growth prospects medical device companies spend a ... development (R&D) than do companies in other industries.  ...
(Date:5/25/2016)... , May 25, 2016 ... & Expo earlier this month, the numbers and momentum ... continue to climb into the billions, more research and ... released 4th Edition State of Legal Marijuana Markets Report ... cannabis-focused data-analysis firm, much of the increase in sector ...
Breaking Medicine Technology: